Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. - Wikidata - awgldk - TriplyDB

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

http://www.wikidata.org/entity/Q35861111

about

Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia.Current status and perspectives of patient-derived xenograft models in cancer research.Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults.The promise of Janus kinase inhibitors in the treatment of hematological malignancies.How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study.B lymphoblastic leukemia/lymphoma: new insights into genetics, molecular aberrations, subclassification and targeted therapy.Philadelphia chromosome-like acute lymphoblastic leukemia.Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia.Why do BCL-2 inhibitors work and where should we use them in the clinic?Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients.Functional precision cancer medicine-moving beyond pure genomics.JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma.How is the Ph-like signature being incorporated into ALL therapy?Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome–like acute B-cell lymphoblastic leukemia.Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance.Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations.SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia.JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias

P2860

Q33578333-D261F0DD-97AF-42A8-9237-2C82F6760BDD Q33667686-78E7DFF9-E0A0-4A6D-A3B7-0C1FE4BACEA9 Q39128765-AC2264C8-F52A-4B55-A569-D4B516F85E37 Q39170500-B945D3EE-A994-44B1-8858-11BA1DBE2EB3 Q41490661-DF2401CA-946D-4822-B574-550B9FD7DBAA Q42371687-9EC102DE-6FE6-4462-9920-1C9A4254F6DD Q43431904-04468570-57E1-466F-99FD-C5743D35432C Q46711660-DE74DD07-3EB0-4E86-A04A-87334ADC662E Q47095048-348144BA-0980-4AC4-94C3-84CC1C0DAE67 Q47159040-4ABB9372-4CC9-483E-9A44-7EE2BE77DABA Q47164848-BCDB0188-4456-4872-BEB4-55E3175C2184 Q48013156-12047C6D-5B3E-402B-A7EF-59953C94370C Q48109284-C4D41255-4F25-4191-9F8D-3F5143747C82 Q50055394-A2BC4CED-8440-40DC-BF4C-BBAC97AF67BC Q50098629-6A1854BA-C2C3-40A7-BACC-94164C025EC5 Q50308754-B5328385-8ACD-4D1C-A728-E4CEE03F8E79 Q52584568-D04C005C-C32F-474E-A08B-0496DA2373CC Q54977480-3A19F205-007E-488D-8375-DF7FCB3B2BBB Q55273917-6DCFED07-806F-4BD9-909B-FBB1D7301F15 Q57272422-D0BD6858-E4F5-44F3-9272-ACCE0CB0D43C

P2860

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

http://www.wikidata.org/entity/Q35861111

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

@ast

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

@en

type

label

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

@ast

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

@en

prefLabel

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

@ast

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

@en

P1433

Q35861111-C12583CD-4E3C-4355-A8DF-A07279C26EAD

P1476

Q35861111-1C694FBE-D7D9-4909-9AEA-C51CE386B6A3

P2093

Q35861111-0E53DBB4-2F8D-439B-B5FE-2D38D26EB194

Q35861111-16600DE7-228F-45AE-8FE9-B5CFE852DA38

Q35861111-1BC8DEDC-452E-4031-828C-AC332ABFDBE7

Q35861111-25A2C89F-108A-4842-BD3C-B1E5F518EA3D

Q35861111-2766C60C-C2CB-46CA-9E1B-6DA76956F9A9

Q35861111-2D5F85EC-6F34-43A5-ADF0-8BCDB1D2420C

Q35861111-2DEAB135-53ED-469A-8823-52E43943D9CD

Q35861111-3173FB31-423A-4D4C-BCA3-F3AD6270AFE8

Q35861111-37BD689E-AEDC-4F7A-9EFE-984475C8FD36

Q35861111-3CB38D1B-DAE4-470F-B428-B54BBFE57852

P2860

Q35861111-00648667-7D8D-4DFE-BA1C-375C7DCF792D

Q35861111-079E0B22-2A87-4173-A746-859854D934C2

Q35861111-12ACD93F-C32A-4A19-B0E1-0DA376E15DB0

Q35861111-12DBEB2C-6FB6-42C9-9058-3A05E530AD08

Q35861111-1D69C147-380C-4E62-9424-A85154644E14

Q35861111-1E5DD645-2800-4E83-8E1A-3937620FD14E

Q35861111-1F71E7D8-231A-450F-AE80-270C553BFE2D

Q35861111-3F3D8447-4E1A-4BD0-B48D-BAA4C6859728

Q35861111-454571F8-827E-4FDB-B84E-84C931EBADD4

Q35861111-48095FDC-985B-4954-BEE5-4CA4F78E2C7A

P304

Q35861111-ED1B2CA1-49A5-454A-8799-B91D7855EF1C

P31

Q35861111-6467CF9A-A7DB-4131-BA3B-60D40A40DC83

P356

Q35861111-7A94E295-64C3-40BD-9B6D-458788C0A2BF

P433

Q35861111-4A179B90-EC33-4484-A3B1-F61C0F71167F

P478

Q35861111-BA2E4851-7817-49C1-A28A-D98D69326D7F

P50

Q35861111-BE568A3D-47B1-44B5-AC8D-C127324CAE56

P577

Q35861111-B77B4C72-820A-47FA-9A2D-2F2CB21CE207

P698

Q35861111-C06A0848-13E7-4253-A2F5-C568D255B037

P921

Q35861111-17B9F8D3-255B-440A-BD5E-E23C7880E052

Q35861111-E29BB023-C1E6-43B4-9009-F2176BFF7879

P932

Q35861111-2FF5C70C-9F21-4CB9-8129-93F3D9572AD8

P356

J.CCELL.2015.06.005

P1433

P1476

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

@en

P2093

Akinori Yoda

http://www.w3.org/2001/XMLSchema#string

Alexandra Christodoulou

http://www.w3.org/2001/XMLSchema#string

Amanda L Christie

http://www.w3.org/2001/XMLSchema#string

Andrew A Lane

http://www.w3.org/2001/XMLSchema#string

Anthony Letai

http://www.w3.org/2001/XMLSchema#string

Arno Dölemeyer

http://www.w3.org/2001/XMLSchema#string

Bjoern Chapuy

http://www.w3.org/2001/XMLSchema#string

Christoph Gaul

http://www.w3.org/2001/XMLSchema#string

Daniel J DeAngelo

http://www.w3.org/2001/XMLSchema#string

Dario Sterker

http://www.w3.org/2001/XMLSchema#string

P2860

Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans

Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805

Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.

Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation.

Pathology of lymphoma in HIV.

EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.

Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.

Cancer burden in the HIV-infected population in the United States

P304

29-41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCELL.2015.06.005

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Martha Wadleigh

P577

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26175414

http://www.w3.org/2001/XMLSchema#string

P921

P932

4505625

http://www.w3.org/2001/XMLSchema#string